We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

A Type of Stem Cell May Repair Hearts

By HospiMedica staff writers
Posted on 08 Apr 2005
A specific type of human fetal stem cell has shown the ability to co-differentiate simultaneously into both muscle and blood vessel cells, a finding that may help to repair damaged hearts. More...


Although a number of studies have confirmed the ability of bone-marrow-derived stem cells to develop into cardiac tissue cells, in more recent trials these stem cells have not shown the ability to incorporate into ailing heart tissue as robustly as originally expected. The results appeared to indicate that something was missing.

Now researchers have found that a specific type of stem cell, bearing a surface antigen called CD133, is unusually adept at differentiating into a variety of organ-specific cell types. Although cells with this biomarker are rare in adult issues, they are abundant in the fetal liver. Using human fetal liver tissues, the researchers isolated CD133+ stem cells, then bathed them in a culture rich in growth factors and other biochemicals, including vascular endothelial growth factor-A (VEGF-A) and brain-derived neurotrophic factor (BDNF).

The researchers then injected cells derived from both CD133+ and CD133- liver stem cells into mice. The CD133+ stem cells developed into pulsating vascularized cardiomyocytes but the CD133- cells did not. This showed that the CD133+ cells were capable of forming both myocytes and angiogenic cells. Because of the potential for immune-system rejection, cells isolated from a patient's own body are the best choice rather than cells from fetal tissue. For this reason, the researchers are investigating whether adult livers might bear traces of CD133+. Pre-conditioning the cells in the laboratory may help ensure that the cells have the essential biologic cues critical for differentiation. The study results were reported in the March 2005 issue of Circulation.

"All these findings are re-igniting interest in using these biochemically activated stem cells to regenerate vascularized tissue,” said Dr. Shahin Rafii, professor of genetic medicine at Weill Cornell Medical College (New York, NY, USA), who led the study. "Some of our research may even help find new sources of expandable CD133+ stem cells within umbilical cord blood or adult bone marrow, livers, or other organs.”


Related Links:
Weill Cornell Medical College

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Digital Radiography System (Ceiling Free)
Digix CF Series
New
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.